s6y

FILANA THERAPEUTICS, INC.

Ticker
FLNA
CIK
1069530
Industry
Pharmaceutical Preparations
Formerly
CASSAVA SCIENCES INC, PAIN THERAPEUTICS INC

Financials 108

  1. 10-Q Quarterly Report for period ending Sep 30, 2026
  2. 10-Q Quarterly Report for period ending Jun 30, 2026
  3. 10-Q Quarterly Report for period ending Mar 31, 2026
  4. 10-K Annual Report for period ending Dec 31, 2025
  5. 10-Q Quarterly Report for period ending Sep 30, 2025
  6. 10-Q Quarterly Report for period ending Jun 30, 2025
  7. 10-Q Quarterly Report for period ending Mar 31, 2025
  8. 10-K Annual Report for period ending Dec 31, 2024
  9. 10-Q Quarterly Report for period ending Sep 30, 2024
  10. 10-Q Quarterly Report for period ending Jun 30, 2024

All 108 financials filings

News 251

  1. 8-K Current report filing
  2. 8-K Current report filing
  3. 8-K Current report filing
  4. 8-K Current report filing
  5. 8-K Current report filing
  6. 8-K Current report filing
  7. 8-K Current report filing
  8. 8-K Current report filing
  9. 8-K Current report filing
  10. 8-K Current report filing

All 251 news filings

Ownership 732

  1. 4 Statement of changes in beneficial ownership of securities
  2. 4 Statement of changes in beneficial ownership of securities
  3. 4 Statement of changes in beneficial ownership of securities
  4. 4 Statement of changes in beneficial ownership of securities
  5. 4 Statement of changes in beneficial ownership of securities
  6. 4 Statement of changes in beneficial ownership of securities
  7. 4 Statement of changes in beneficial ownership of securities
  8. 3 Initial statement of beneficial ownership of securities
  9. 4 Statement of changes in beneficial ownership of securities
  10. 4 Statement of changes in beneficial ownership of securities

All 732 ownership filings

Prospectus 52

  1. 424B2 Prospectus filed pursuant to Rule 424(b)(2)
  2. S-3 Registration statement for specified transactions by certain issuers
  3. 424B2 Prospectus filed pursuant to Rule 424(b)(2)
  4. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  5. S-3ASR Automatic shelf registration statement of securities of well-known seasoned issuers
  6. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  7. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  8. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  9. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  10. S-3ASR Automatic shelf registration statement of securities of well-known seasoned issuers

All 52 prospectus filings

Proxies 32

  1. DEF 14A Definitive proxy statements
  2. DEF 14A Definitive proxy statements
  3. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  4. DEF 14A Definitive proxy statements
  5. DEF 14A Definitive proxy statements
  6. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  7. DEF 14A Definitive proxy statements
  8. DEF 14A Definitive proxy statements
  9. DEF 14A Definitive proxy statements
  10. DEF 14A Definitive proxy statements

All 32 proxies filings

Other 56

  1. ARS Annual report to security holders
  2. EFFECT Notice of Effectiveness
  3. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  4. SCHEDULE 13G/A
  5. SCHEDULE 13G/A
  6. ARS Annual report to security holders
  7. 144 Filing for proposed sale of securities under Rule 144
  8. 144 Filing for proposed sale of securities under Rule 144
  9. SCHEDULE 13G/A
  10. SCHEDULE 13G

All 56 other filings